Your session is about to expire
← Back to Search
Cohort A: Delandistrogene Moxeparvovec for Duchenne Muscular Dystrophy
Study Summary
This trial is testing a new gene therapy for Duchenne Muscular Dystrophy in boys. The boys will receive the therapy through IV. The trial will test the safety of the therapy in two groups of boys, 3 months to 3 years old, and 4 to 7 years old.
- Duchenne Muscular Dystrophy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available positions for subjects in this research project?
"This particular study is no longer recruiting patients, however based on the information found on clinicaltrials.gov, it appears that the study was last edited on 7/4/2022 and was originally posted on 1/4/2018. There are 88 other studies that are actively searching for candidates right now."
Are people of all ages being accepted for this clinical trial?
"3 month old to 7 year olds are the only age group applicable for this particular trial. Out of the total 111 trials, 61 are designed for children and 50 are meant for elderly patients."
For which kind of patients is this research relevant?
"This clinical trial is testing a new medication for Duchenne muscular dystrophy and is currently looking for 4 participants that meet the following eligibility criteria: 3 months to 7 years old, definitive diagnosis of DMD, ability to cooperate with motor assessment testing, no previous treatment with corticosteroids (for Cohort A), or stable dose of oral corticosteroids for at least 12 weeks prior to screening (for Cohort B)."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger